ID

37944

Descripción

Study of the P16 Gene as a Predictor of Myelosuppression in Breast Cancer Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01305954

Link

https://clinicaltrials.gov/show/NCT01305954

Palabras clave

Versiones (1)
  1. 2/9/19 2/9/19 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

2 de septiembre de 2019

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Breast Cancer NCT01305954

Inglés

Eligibility Breast Cancer NCT01305954

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
≥ 18 years of age;
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
histologically confirmed stage i-iv breast cancer;
Descripción

Breast Carcinoma TNM Breast tumor staging

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0678222
UMLS CUI [1,2]
C0474926
ecog performance status 0-3;
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
scheduled to start a new course of chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or recurrent disease;
Descripción

Chemotherapy cycle Neoadjuvant Scheduled | Chemotherapy cycle Adjuvant Scheduled | Chemotherapy cycle Scheduled Neoplasm Metastasis | Disease Newly Diagnosed | Recurrent disease

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1302181
UMLS CUI [1,2]
C0600558
UMLS CUI [1,3]
C0205539
UMLS CUI [2,1]
C1302181
UMLS CUI [2,2]
C1522673
UMLS CUI [2,3]
C0205539
UMLS CUI [3,1]
C1302181
UMLS CUI [3,2]
C0205539
UMLS CUI [3,3]
C0027627
UMLS CUI [4,1]
C0012634
UMLS CUI [4,2]
C1518321
UMLS CUI [5]
C0277556
growth factors, e.g., filgrastim, pegfilgrastim, are allowed, but their dose and duration will be tracked.
Descripción

Growth Factors | Filgrastim | pegfilgrastim

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0018284
UMLS CUI [2]
C0210630
UMLS CUI [3]
C1136535
absolute lymphocyte count (alc) > 500 cells/μl as determined by routine cbc with differential;
Descripción

Absolute lymphocyte count | Complete blood count with differential

Tipo de datos

boolean

Alias
UMLS CUI [1]
C3544087
UMLS CUI [2]
C0545131
signed, irb approved written informed consent.
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
presence of acute, active infection;
Descripción

Communicable Disease

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009450
history of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia);
Descripción

Bone Marrow Disease Clonal | MYELODYSPLASTIC SYNDROME | Myeloproliferative disease | Acute leukemia | Chronic leukemia

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0005956
UMLS CUI [1,2]
C1522642
UMLS CUI [2]
C3463824
UMLS CUI [3]
C0027022
UMLS CUI [4]
C0085669
UMLS CUI [5]
C1279296
other co-morbid illness which would impair ability to participate in the study;
Descripción

Comorbidity Impairing Study Subject Participation Status

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0009488
UMLS CUI [1,2]
C0221099
UMLS CUI [1,3]
C2348568
concurrent experimental therapy (note: concurrent biologic therapy is permitted, provided it is not experimental).
Descripción

Therapy, Investigational | Biological treatment Standard allowed

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0949266
UMLS CUI [2,1]
C1531518
UMLS CUI [2,2]
C1442989
UMLS CUI [2,3]
C0683607
prior or current receipt of histone deacetylase (hdac) inhibitors
Descripción

Histone deacetylase inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1512474
Volver a la parte superior de la página

Similar models

Eligibility Breast Cancer NCT01305954

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
≥ 18 years of age;
boolean
C0001779 (UMLS CUI [1])
Breast Carcinoma TNM Breast tumor staging
Item
histologically confirmed stage i-iv breast cancer;
boolean
C0678222 (UMLS CUI [1,1])
C0474926 (UMLS CUI [1,2])
ECOG performance status
Item
ecog performance status 0-3;
boolean
C1520224 (UMLS CUI [1])
Chemotherapy cycle Neoadjuvant Scheduled | Chemotherapy cycle Adjuvant Scheduled | Chemotherapy cycle Scheduled Neoplasm Metastasis | Disease Newly Diagnosed | Recurrent disease
Item
scheduled to start a new course of chemotherapy in the neo-adjuvant, adjuvant or metastatic setting for newly diagnosed or recurrent disease;
boolean
C1302181 (UMLS CUI [1,1])
C0600558 (UMLS CUI [1,2])
C0205539 (UMLS CUI [1,3])
C1302181 (UMLS CUI [2,1])
C1522673 (UMLS CUI [2,2])
C0205539 (UMLS CUI [2,3])
C1302181 (UMLS CUI [3,1])
C0205539 (UMLS CUI [3,2])
C0027627 (UMLS CUI [3,3])
C0012634 (UMLS CUI [4,1])
C1518321 (UMLS CUI [4,2])
C0277556 (UMLS CUI [5])
Growth Factors | Filgrastim | pegfilgrastim
Item
growth factors, e.g., filgrastim, pegfilgrastim, are allowed, but their dose and duration will be tracked.
boolean
C0018284 (UMLS CUI [1])
C0210630 (UMLS CUI [2])
C1136535 (UMLS CUI [3])
Absolute lymphocyte count | Complete blood count with differential
Item
absolute lymphocyte count (alc) > 500 cells/μl as determined by routine cbc with differential;
boolean
C3544087 (UMLS CUI [1])
C0545131 (UMLS CUI [2])
Informed Consent
Item
signed, irb approved written informed consent.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Communicable Disease
Item
presence of acute, active infection;
boolean
C0009450 (UMLS CUI [1])
Bone Marrow Disease Clonal | MYELODYSPLASTIC SYNDROME | Myeloproliferative disease | Acute leukemia | Chronic leukemia
Item
history of clonal bone marrow disorder (i.e., myelodysplastic or myeloproliferative disorder, acute or chronic leukemia);
boolean
C0005956 (UMLS CUI [1,1])
C1522642 (UMLS CUI [1,2])
C3463824 (UMLS CUI [2])
C0027022 (UMLS CUI [3])
C0085669 (UMLS CUI [4])
C1279296 (UMLS CUI [5])
Comorbidity Impairing Study Subject Participation Status
Item
other co-morbid illness which would impair ability to participate in the study;
boolean
C0009488 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C2348568 (UMLS CUI [1,3])
Therapy, Investigational | Biological treatment Standard allowed
Item
concurrent experimental therapy (note: concurrent biologic therapy is permitted, provided it is not experimental).
boolean
C0949266 (UMLS CUI [1])
C1531518 (UMLS CUI [2,1])
C1442989 (UMLS CUI [2,2])
C0683607 (UMLS CUI [2,3])
Histone deacetylase inhibitor
Item
prior or current receipt of histone deacetylase (hdac) inhibitors
boolean
C1512474 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial